Pay makers of new antibiotics a fixed yearly amount that countries chip in together, not by how much they sell
In short
- Each year, countries pay a company a fixed amount for a new last-resort antibiotic, not an amount based on how much is sold.
- The money comes from a shared fund that each country pays into according to the size of its economy.
- The company stops marketing the drug and promises that it will not be used carelessly.
- The company is responsible for getting the same drug to hospitals in poor countries cheaply and reliably.
If this comes true
In a small hospital in a port town, a baby born too early catches a germ that medicines can barely touch, but a new antibiotic is already on the shelf, and the family starts treatment without worrying about the price.
Perhaps
A health official in one country might have to put off rebuilding a village clinic for a year to pay the yearly fee for a drug that was used on only a few people last year.
Water so far 💧 0
The proposal in detail
The plan covers new antibacterial drugs that work against germs that current medicines can no longer kill, and only those that an international review board of experts from many countries has judged to be a needed last resort for society. The company that develops an approved drug signs a contract of about ten years with the shared fund and receives a fixed amount each year. The amount is set by scoring points such as how serious a resistant germ the drug works against, how different it is from existing drugs, and whether it comes in a form that can be used for children and in hospitals with poor equipment. In return, the company does not earn profit based on how much is sold, and the drug is supplied at a price close to what it costs to make. The company is required not to promote the drug to doctors, to help hospitals use it only for the patients who need it, to apply for approval in low-income countries too and deliver the drug without running out of stock, and to keep up its ability to manufacture it. Contributions to the fund are assigned according to the size of each country's economy and its population, and low-income countries are exempt. Wealthy countries that do not contribute can still buy the drug, but they pay a price above the cost of making it. If the drug later turns out to be not effective enough, or a safety problem is found after the contract is signed, payments stop. A small separate payment is also set aside to keep up the steady supply of older antibacterial drugs that have no replacement, so that they do not stop being made.
BenefitsKeeping a drug in reserve and keeping development going no longer conflict
By cutting a company's income off from the amount it sells, the plan removes the contradiction that the more a drug is sold, the more resistance grows. The company is rewarded even if the drug sits on a shelf and is used only a few times a year, so doctors can use the last-resort drug only for patients who truly need it, and companies get a reason to return to antibacterial research. A single country making such payments alone would be too small to move companies around the world, but when countries pool their money, they can show a solid outlook that is enough to keep development going. Because contributions match the size of each economy, poor countries are exempt, and the company is made responsible for supply, the new drug is more likely to reach the regions hit hardest by resistant germs without delay and at a low price. Hospitals can also choose drugs according to what patients need, not according to how high the price is. It is like insurance shared across the world, protecting a foundation that usually goes unnoticed but whose loss would bring down all of medicine. Once resistant germs have spread, rushing to make a drug is too late, because development takes ten years or more. That time can be bought only by paying in advance and continuing to pay.
DrawbacksThe weight of paying tax money every year for a drug that is barely used
Under this plan, the fund keeps paying a large amount even in years when almost no patients use the drug. That money comes out of uses such as vaccines, clean water, and clinics close to people's homes, where the same amount might reliably save many more lives. On top of that, the point scoring that decides how much to pay for which drug is hard to do well, and there is room for a company to try to make its drug look more valuable by lobbying experts. If the plan ends up paying for ten years for a drug that is not that valuable, it cannot be undone. Many people are likely to feel strong resistance to using public money to guarantee the profits of a big drug company in advance. It is also not easy to keep every country agreeing to its share of the contributions. If some countries try to take the benefits without paying and the agreement falls apart, companies that started development counting on this plan could pull out all at once, and the situation might become even less stable than it is now. Furthermore, because these payments are a reward after a drug is finished, they do not solve the earlier problem that there are few promising ideas for research to begin with. Even after investing a huge amount, there is still a chance that fewer new drugs will appear than hoped.
Learn the background
Antibacterial drugs are the foundation of medicine, supporting surgery, childbirth, cancer treatment, and the lives of babies born too early. But the more they are used, the more germs get used to them and stop responding. These resistant germs are spreading around the world, and more people are dying because drugs do not work on them. Even so, almost no companies that make new antibacterial drugs are left. The reason is clear. The right way to use a new antibacterial drug is to keep it as a last resort, used only when other drugs fail, so that resistance does not develop. But a drug company's income depends on how much it sells, so the more correctly a drug is used, the less it sells, and the company cannot make back the cost of developing it. There are cases where a company struggled all the way to approval and then ran into financial trouble because the drug did not sell. What society needs from the drug and what earns the company money point in opposite directions. Simply increasing research grants does not solve the problem of a drug being made and then getting stuck in the market. If this is left alone, the people who will suffer are people all over the world who want to have ordinary surgery or give birth safely, and above all patients in poor countries, where resistant germs spread more easily and new drugs are harder to get.
Choose them ready to accept their drawbacks too (up to 5)
It helps pay for the server and the AI's planting
This proposal was written in Japanese by AI (claude-opus-5-5, policy version 2026-10-20b) and translated by AI (claude-sonnet-5-5). Nobody has checked the facts. Read the original (日本語) How the AI writes